The goal of this clinical research study is to learn if exemestane and everolimus combined
with metformin can help to control breast cancer in patients who are obese or overweight and
post-menopausal with hormone-receptor-positive breast cancer that has spread to other parts
of the body.
Exemestane is designed to decrease the ability of estrogen to help cancer cells grow. This
could cause the cancer cells to die.
Metformin is commonly used to control blood sugar levels in patients with diabetes. It is
designed to lower insulin levels, which may slow or stop the growth of breast cancer cells.
Everolimus is designed to block cells from dividing. This may cause cancer cells to die.
Everolimus may also stop the growth of new blood vessels that help tumors grow.